Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

OSE Immunotherapeutics to present the preclinical data of its new checkpoint inhibitor Effi-DEM on SIRP-a/CD47 strategic pathway at the 2016 Immune Checkpoint Inhibitors Conference

OSE Immunotherapeutics
Posted on: 04 Oct 16

Nantes, Paris, October 4, 2016 - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE), a biotechnology company developing immunotherapies of activation and regulation in immuno-oncology, auto-immune diseases and transplantation, will present in an oral session preclinical studies results for Effi-DEM, a new generation checkpoint inhibitor targeting Myeloid Derived Suppressor Cells (MDSC) and Tumor Associated Macrophages (TAM), at the ICI (Immune Checkpoint Inhibitors) conference (Munich, November 16th to 18th, 2016).

 

Bernard Vanhove, Chief Operating Officer of OSE Immunotherapeutics, in charge of R&D and International scientific collaborations, will present and comment all of the data from its preclinical studies conducted with Effi-DEM both in vivo and in vitro and in various cancer models. 

Effi-DEM, a new generation checkpoint inhibitor specifically targeting the SIRP- α receptor on the strategic SIRP-α/CD47 pathway, has the potential to transform suppressor myeloid and macrophage cells in non-suppressive cells, thereby inducing a reactivation of the immune response, an anti-tumor impact and an immune memory.

SIRP-α is a receptor strongly expressed by Myeloid Derived Suppressor Cells (MDSC) and Tumor Associated Macrophages (TAM) and its ligand is CD47. Suppressor immune cells MDSC and TAM play a key role in tumor growth of inflammatory cancers.

Effi-DEM has shown to be effective in various aggressive cancer models with encouraging preclinical results, both in monotherapy and in therapeutic combinations with anti-PD-L1 (checkpoint inhibitors) and anti-CD137 (4-1BB), activators of the T-cell response. Significant efficacy and survival increase data were demonstrated in hepatocarcinoma, melanoma and triple negative breast cancer models.

 “These preclinical results validate the therapeutic potential of our new generation checkpoint inhibitor Effi-DEM in immuno-oncology, and show how the product enhances immune response by targeting novel checkpoint SIRP-α/CD 47 pathway. OSE Immunotherapeutics is at the forefront of this new immuno-oncology area and clearly focuses in developing such an innovative product”, commented Dominique Costantini, Chief Executive Officer of OSE Immunotherapeutics.

Details of the presentation are as follows:

Title: Selective Targeting of The SIRP-α Immune Checkpoint To Dampen Suppression By Myeloïd-Derived Suppressor Cells And Control Polarization Of Human Macrophages

Date/Time: Thursday, November 17, 2016, 10:30am CET
Location: Maritim Hotel München, Goethestraße 7, 80336 Munich, Germany

These preclinical data will also be presented in an abstract at the Annual World Gene Convention-2016 (WGC-2016), which will be held during November 3-5, 2016 in Shanghai, China.

About ICI (IMMUNE CHECKPOINT INHIBITORS) EUROPE

ICI Europe is a forum dedicated to immune checkpoint inhibitors. It focuses specifically on the preclinical, translational and clinical challenges that drug developers face in advancing more checkpoint inhibitors onto the market. Combining data driven case studies with interactive experience sharing sessions, its program provides cutting edge insights into novel checkpoint pathways, more predictive preclinical models, the optimal combination strategies, patient stratification biomarkers and emerging clinical trial data.

 

ABOUT WGC (ANNUAL WORLD GENE CONVENTION)

WGC-2016 features a very strong technical program, mainly focused on breakthroughs in DNA and RNA research, advances of genomics & genetics, the frontier research of life sciences. It aims to provide a platform for all experts from academia, industry and national labs to discuss latest hot researches and achievements.

ABOUT OSE IMMUNOTHERAPEUTICS

Our ambition is to become a world leader in activation and regulation immunotherapies

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 04/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.